Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 15/20 | 0.41 |
| ▸ | MAOB | P27338 | 14/20 | 0.41 |
| ▸ | MAOA | P21397 | 13/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23466001 | 1.00 | HTR2A (0.44) | HTR2AKDM1AMAOBMAOAOPRD1 | |
| SCHEMBL19629563 | 1.00 | HTR2A (0.44) | HTR2AKDM1AMAOBMAOAOPRD1 | |
| SCHEMBL17725095 | 1.00 | HTR2A (0.44) | HTR2AKDM1AMAOBMAOAOPRD1 | |
| SCHEMBL17725107 | 1.00 | HTR2A (0.44) | HTR2AKDM1AMAOBMAOAOPRD1 | |
| SCHEMBL19629494 | 1.00 | HTR2A (0.44) | HTR2AKDM1AMAOBMAOAOPRD1 | |
| SCHEMBL17712743 | 0.89 | OPRM1 (0.45) | KDM1AMAOBMAOAOPRD1OPRM1 | |
| SCHEMBL17712914 | 0.89 | OPRM1 (0.45) | KDM1AMAOBMAOAOPRD1OPRM1 | |
| SCHEMBL17713072 | 0.84 | HTR2A (0.43) | HTR2AKDM1AMAOBMAOAOPRD1 | |
| SCHEMBL21418971 | 0.82 | LIG1 (0.42) | HTR2AKDM1AOPRM1 | |
| SCHEMBL21418957 | 0.82 | LIG1 (0.42) | HTR2AKDM1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | HTR2A 80/4885KDM1A 3812/4885MAOB 248/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | HTR2A 80/4885KDM1A 3812/4885MAOB 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.